Full text is available at the source.
Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity
Long-term treatment with combined glucagon-like peptide-1 and glucagon receptor activators improves fatty liver in obese mice without weight loss
AI simplified
Abstract
Dicretin led to a superior reduction of hepatic lipid content compared to Semaglutide or equivalent weight loss from calorie restriction.
- GCGR-biased co-agonists may effectively reduce liver fat in mice with diet-induced obesity.
- All treatment groups showed improvements in glucose tolerance and insulin resistance.
- Unique changes in gene and metabolite expression were observed in Dicretin-treated mice.
- Some identified changes relate to glucagon signaling, while others remain unclear in their physiological roles.
AI simplified